IDH1 and acute myeloid leukemia: In addition, the ivosidenib/venetoclax combination, in a clinical trial, was administered as a therapeutic combination alone or in triplet with azacytidine in IDH1-mutated MDS, ND, and R/R AML with promising results [141].